Production (Stage)
Ondine Biomedical Inc.
OBIMF
$0.14
$0.00392.87%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 67.62% | 81.70% | 101.00% | 93.52% | 82.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.62% | 81.70% | 101.00% | 93.52% | 82.40% |
| Cost of Revenue | 43.39% | 50.40% | 57.34% | 49.08% | 38.26% |
| Gross Profit | 84.85% | 107.63% | 146.54% | 143.16% | 135.87% |
| SG&A Expenses | 10.56% | -11.66% | -30.18% | -26.29% | -23.15% |
| Depreciation & Amortization | -7.53% | -2.50% | 2.12% | 10.83% | 19.52% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.04% | 6.31% | -16.42% | -18.02% | -20.29% |
| Operating Income | -29.15% | -1.75% | 21.55% | 22.34% | 23.78% |
| Income Before Tax | -30.31% | 0.03% | 24.64% | 26.09% | 28.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.31% | 0.03% | 24.64% | 26.09% | 28.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.31% | 0.03% | 24.64% | 26.09% | 28.11% |
| EBIT | -29.15% | -1.75% | 21.55% | 22.34% | 23.78% |
| EBITDA | -29.64% | -1.90% | 21.62% | 22.48% | 23.98% |
| EPS Basic | 7.37% | 21.69% | 33.43% | 30.81% | 28.93% |
| Normalized Basic EPS | 9.25% | 21.52% | 31.92% | 29.07% | 27.31% |
| EPS Diluted | 7.37% | 21.69% | 33.43% | 30.81% | 28.93% |
| Normalized Diluted EPS | 9.25% | 21.52% | 31.92% | 29.07% | 27.31% |
| Average Basic Shares Outstanding | 39.31% | 26.37% | 13.27% | 7.29% | 1.30% |
| Average Diluted Shares Outstanding | 39.31% | 26.37% | 13.27% | 7.29% | 1.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |